UK Rheumatology Drugs Market Analysis Report [2022-30]

UK Rheumatology Drugs Market Analysis

$ 3999

The UK Rheumatology Drugs Market is projected to grow from $1.587 Bn in 2022 to $1.692 Bn by 2030, registering a CAGR of 0.8% during the forecast period of 2022 - 2030. Because of the high prevalence of rheumatic diseases in the nation and the availability of a top-notch healthcare system there, the market in the UK is predicted to have minimal growth over the next five years. The key players in the UK rheumatology drugs market include Pfizer, Roche, AbbVie, Merck & Co., Eli Lilly, and Company, AstraZeneca, Novartis

ID: IN10GBPH022 CATEGORY: Pharmaceuticals GEOGRAPHY: UK AUTHOR: Shivam Zalke

Buy Now

UK Rheumatology Drugs Market Executive Summary

The UK Rheumatology Drugs Market is projected to grow from $1.587 Bn in 2022 to $1.692 Bn by 2030, registering a CAGR of 0.8% during the forecast period of 2022 - 2030.

Because of the high prevalence of rheumatic diseases in the nation and the availability of a top-notch healthcare system there, the market in the UK is predicted to have minimal growth over the next five years. More than 10 million individuals in the UK suffer from arthritis and associated diseases, according to the National Health Service. This is expected to have a substantial impact on the demand for various anti-rheumatic drug types and, in turn, favorably affect market growth in the nation over the next few years. Additionally, rising healthcare costs make it possible for people to access pricey medical procedures and medications, which is anticipated to have a favorable effect on market expansion in the UK throughout the course of the forecast period.

Additionally, the market for various types of antirheumatic drugs will grow due to the increasing demand for disease treatment caused by the growing number of geriatric people in the United Kingdom who are 65 years of age and older. These individuals suffer from age-related diseases like rheumatoid arthritis, back pain, and joint pain, among others.

UK rheumatology drugs market analysis

Market Dynamics

Market Drivers

The UK rheumatology drugs market is a large and growing market, driven by factors such as:

Increasing prevalence of rheumatic diseases: The prevalence of rheumatic diseases, such as osteoarthritis, rheumatoid arthritis, and lupus, among others, is increasing in the UK, driving demand for effective treatments
The growing use of biologic drugs: Biologic drugs, such as tumor necrosis factor (TNF) inhibitors, are becoming increasingly popular in the treatment of rheumatic diseases in the UK, due to their improved efficacy compared to traditional treatments
Expansion of the generics market: The generics market is growing in the UK, driven by the increasing availability of generic versions of patented drugs and the ongoing focus on reducing healthcare costs
Advances in drug development: Advances in drug development are expected to continue to drive growth in the UK rheumatology drugs market, with the introduction of new and innovative treatments that offer improved efficacy and safety compared to traditional treatments
Increasing focus on patient outcomes: There is an increasing focus on patient outcomes in the UK rheumatology drugs market, with healthcare providers and payers looking to improve the quality of care for patients with rheumatic diseases

Overall, these trends are expected to shape the future of the UK rheumatology drugs market, driving growth and shaping the market landscape in the coming years.

Competitive Landscape

Key Players

The key players in the UK rheumatology drugs market include:

Pfizer
Roche
AbbVie
Merck & Co.
Eli Lilly and Company
AstraZeneca
Novartis
Sanofi
Janssen Pharmaceuticals (Johnson & Johnson)
Amgen Inc.

These companies manufacture and market various rheumatoid arthritis drugs, such as tumor necrosis factor (TNF) inhibitors, interleukin-6 (IL-6) inhibitors, and others.

Healthcare Policies and Regulatory Landscape

The UK rheumatology drugs market is subject to various healthcare policies and regulatory frameworks set by the UK government and relevant regulatory agencies such as the National Institute for Health and Care Excellence (NICE) and the Medicines and Healthcare products Regulatory Agency (MHRA).

NICE is responsible for providing guidance on the use of new and existing medicines in the NHS, including those used in the treatment of rheumatological conditions. NICE appraises new drugs and technologies based on their clinical and cost-effectiveness and provides recommendations on their use in the NHS.

The MHRA is responsible for the regulation of all medicines and medical devices in the UK. It assesses the quality, safety, and efficacy of new drugs, and grants marketing authorization for those that meet the required standards. The MHRA also monitors the safety of marketed drugs and can take action to withdraw or restrict the use of drugs if they are found to be unsafe.

In terms of policy, the UK government has set a number of initiatives aimed at improving access to new and innovative medicines, including the Accelerated Access Collaborative (AAC) and the Innovation and Technology Tariff (ITT). The AAC is a partnership between the NHS, industry, and academia aimed at accelerating the uptake of innovative medicines, devices, and diagnostics. The ITT provides a financial incentive for the NHS to adopt innovative treatments, by linking reimbursement to the adoption of new treatments.

Overall, the UK rheumatology drugs market is subject to a robust regulatory and policy environment that aims to ensure the safety, efficacy, and cost-effectiveness of new drugs, and to promote innovation and access to new treatments for patients.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Rheumatology Drug Market Segmentation

Drug Class

The disease-modifying anti-rheumatic drugs (DMARDs) is the major revenue contributor. Rise in awareness related to the use of DMARDs, surge in prevalence of rheumatoid arthritis, rise in obese & overweight population across the globe, and increase in adoption of DMARDs as a first-line treatment for rheumatoid arthritis are the key factors that boost the growth of the segment.

Disease-modifying anti-rheumatic drugs (DMARDs)
Nonsteroidal anti-inflammatory drugs (NSAIDs)
Corticosteroids
Uric acids
Others

Route of administration

Oral
Parental

Sales channel

Depending on the sales channel, the prescription-based drug segment is the major shareholder in the UK rheumatoid drugs market, owing to the advantages offered by prescription-based drugs.

Prescription-based drugs
OTC

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.